<DOC>
	<DOC>NCT00254696</DOC>
	<brief_summary>- To determine the value of using piperacillin/tazobactam in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection. - To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre and post intervention in the selected medical centers.</brief_summary>
	<brief_title>Study Evaluating Antibiotic Utilization Measures and Control of Extended-Spectrum-Lactamases (ESBLs)</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<criteria>Patients admitted or transferred to the ICU/pulmonary/hematology units. Patients of either sex, 18 years of age or older Pregnant and nursing women. Female of childbearing potential without using any birth control methods. Female of childbearing potential using oral contraceptives during study period. (Note: penicillin and betalactamase inhibitors may prevent oral contraceptives from working properly, increasing the chance of pregnancy). Patients who have the contraindications of using Tazocin (pipercillin/tazobactam) Other exclusions apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>bacterial infection</keyword>
</DOC>